At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 266 enrolled
Drug / intervention
Indocyanine Green Tracerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Controlled Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Gastric Cancer
In Brief
A Phase 2 clinical trial evaluating Indocyanine Green Tracer for Stomach Neoplasms and Indocyanine Green. Completed, enrolled 266 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the clinical outcomes of Indocyanine Green Tracer using in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma（cT1-4a, N-/+, M0）.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Neoplasms, Indocyanine Green
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartOct 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedFeb 13, 2017
Enrollment StartOct 15, 2017
Primary CompletionJul 13, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.4 years ago
Interventions
Indocyanine Green Tracerdrug
Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer